Press Release for the fourth Quarter and year ended March 31, 2026 results.
MEDANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts more than Nifty Midcap 150 and 2.5 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medanta delivered strong FY2026 results with total income of INR 45,089 million, up 19.6% year-on-year. EBITDA excluding Noida grew 18.6% to INR 11,343 million with 25.7% margins, while PAT rose 15.1% to INR 5,541 million. The newly operational Noida hospital (382 beds) reported revenue of INR 906 million but still posted an EBITDA loss of INR 783 million, though quarterly losses are declining. Q4 FY26 was the highest ever quarterly revenue at INR 11,958 million, up 25.3% y-o-y. The company added 623 beds during FY26 (20.5% bed growth) across Noida, Patna, and a new 110-bed Ranchi hospital. Volumes remained robust with inpatient count up 16% and outpatient count up 18.7%. ARPOB grew 6.1% to INR 66,550. The board recommended a dividend of INR 0.50 per share.
Strong operational execution and margin improvement outside Noida support the stock. The Noida facility's declining losses and upcoming expansion plans (500 beds in 12 months, 2,700 beds in 3-4 years) provide multi-year growth visibility. Shareholders can expect continued steady performance as Noida reaches maturity.